**Supplementary material**

**Supplementary table 1: Association between clinical or laboratory factors with echocardiographic parameters at the time of the first echocardiography (multivariable analysis with echocardiographic parameter as the endpoint) using an additional adjustment on atrial fibrillation (AF) status**

|  |
| --- |
| **LAVI determinants** |
|  | **exp (Beta)\* ± SD** | **P** |
| Pre-KT hypertension | 1.312 ± 1.122 | 0.025 |
| Valvular heart disease | 1.574 ± 1.129 | 0.0007 |
| Causal nephropathyGlomerulonephritisIgA nephropathyNephroangiosclerosisPolycystic diseaseOtherMalformative uropathy (ref) | 1.007 ± 1.1420.786 ± 1.1380.787 ± 1.1721.042 ± 1.1671.059 ± 1.162 | 0.06 |
| AVF closing  | 0.868 ± 1.089 | 0.11 |
| Pre-KT AFDe novo AFNone (ref) | 1.016 ± 1.1761.167 ± 1.122 | 0.41 |
| **LVEF determinants** |
|  | **Beta ± SE** | **P** |
| Pre-KT diabetes | 7.139 ± 3.244 | 0.031 |
| Post-KT eGFR (ml/min/1.73m2) | 0.139 ± 0.054 | 0.012 |
| Post-KT use of ACEi/ARB | 4.801 ± 2.174 | 0.031 |
| Pre KT AFDe novo AFNone (ref) | -0.531 ± 4.346-5.225 ± 3.396 | 0.31 |

KT: kidney transplantation; AVF: arteriovenous fistula; AF: atrial fibrillation; LAVI: left atrial volume index(mL/m2); LVEF: left ventricular ejection fraction (%); eGFR: estimated glomerular filtration rate (ml/min/1.73m2); ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker.

\*In light of the distribution of LAVI, LAVI was log-transformed. exp(Beta) coefficient is reported to express associations with LAVI (rather than its log). Importantly, exp(Beta) should be interpreted on a multiplicative scale: e.g., patients with a history of pre-KT hypertension have 33% higher (exp[B]=1.329) LAVI than patients without.

**Supplementary table 2: Association between clinical or laboratory factors with changes in echocardiographic parameters between the first and second echocardiography during follow-up (Δ=TTE2 – TTE1)) using an additional adjustment on atrial fibrillation (AF) status**

|  |  |  |
| --- | --- | --- |
|  | **Beta ± SD** | **P** |
| **Determinants of change in LAVI** **(LAVI2- LAVI1)** |
| LAVI (mL/m2) at the time of TTE1 | -0.325 ± 0.156 | 0.043 |
| Male sex | 7.868 ± 2.931 | 0.010 |
| Pre-KT hypertension | 9.725 ± 4.232 | 0.026 |
| ECD \*(LD as reference) | 3.814 ± 3.660 | 0.30 |
| SCD \*(LD as reference)  | -5.657 ± 4.109 | 0.17 |
| Induction therapy with ATG (basiliximab as reference) | 8.075 ± 3.116 | 0.013 |
| Pre KT AFDe novo AFNone (ref) | 2.132 ±5.565-0.688 ±4.559 | 0.90 |
| **Determinants of change in LVEF (LVEF2-LVEF1)** |
| 4-cavity LVEF at the time of TTE1 | -0.825 ± 0.173 | <0.0001 |
| Haemoglobin at the time of TTE1 (g/dl)> median (>12.9g/dL) | 6.027 ± 3.034 | 0.052 |
| ACEi/ARB | 8.269 ± 3.245 | 0.013 |
| Pre KT AFDe novo AFNone (ref) | -0.108 ± 6.1530.538 ± 5.557 | 0.99 |

\* p for the difference between EDC and SCD =0.0064

LAVI: left atrial volume index; KT : kidney transplantation; ECD: expanded criteria donor; SCD: standard criteria donor; LD: living donor; ATG: anti-thymocyte globulin; AF : atrial fibrillation; LVEF: left ventricular filtration ejection; eGFR: estimated glomerular filtration rate; ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker